---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-044541"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:21:21.171021+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M

## Summary
- Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).
- Net income $1.9M ($0.02 EPS) vs net loss $1.0M ($0.01 loss) in Q3 2023.
- Record Adjusted EBITDA $2.9M, up from $0.5M YoY; operating cash $32.4M.
- Niagen ingredient sales $6.7M (+368% YoY); Tru Niagen sales $18.1M (+4% YoY).
- Expanded Niagen+ to >100 wellness clinics; pursuing FDA IND for Ataxia Telangiectasia.

## SEC filing metadata
- accession: 0001628280-24-044541
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024044541/0001628280-24-044541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024044541/cdxc-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-044541
- JSON: https://secwatch.observer/filing/0001628280-24-044541.json
- Plain text: https://secwatch.observer/filing/0001628280-24-044541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.